eBulletin Newsletter

NCCN Flash Updates: NCCN Guidelines Updated for Head and Neck Cancers

NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®), and the NCCN Drugs & Biologics Compendium (NCCN Compendium^®) for Head and Neck Cancers. These NCCN Guidelines^® are currently available as Version 5.2024.

Link directly to the Updates section of the NCCN Guidelines: Head and Neck Cancers

SALI-B

• Useful in Certain Circumstances, regimen added for NTRK gene fusion-positive tumors: Repotrectinib
  • Reference added: Solomon B, Drilon A, Lin JJ, et al. Repotrectinib in patients with NTRK fusion-positive advanced solid tumors, including non-small cell lung cancer: update from the phase 1/2 TRIDENT-1 trial. Poster presented at the European Society for Medical Oncology Congress, Madrid, Spain, October 20-24, 2023.

FOLL-A (1 of 2)

• Bullet 2 modified: "...insulin-like growth factor 2 1 (IGF-2 1)..."

MS-1

• The discussion section has been updated to reflect the changes in the algorithm (repotrectinib addition for salivary gland tumors).